Ingramon, a Peptide Inhibitor of MCP-1 Chemokine, Reduces Migration of Blood Monocytes Stimulated by Glioma-Conditioned Medium
- Autores: Krasnikova T.1, Arefieva T.1, Pylaeva E.1, Sidorova M.1
-
Afiliações:
- Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
- Edição: Volume 160, Nº 4 (2016)
- Páginas: 480-482
- Seção: Oncology
- URL: https://journals.rcsi.science/0007-4888/article/view/236744
- DOI: https://doi.org/10.1007/s10517-016-3201-0
- ID: 236744
Citar
Resumo
Malignant gliomas are most common and fatal primary brain tumors. In addition to neoplastic cells, the tumor tissue contains microglial cells and monocyte-derived macrophages. It is an established fact that monocyte recruiting promotes the tumor growth and dissemination. Monocyte chemotactic protein-1 (MCP-1) is the major attractant for monocytes. We have previously synthesized an MCP-1 antagonist ingramon, a synthetic peptide fragment (65–76) of this chemokine. In the present study, we demonstrated that glioma-conditioned medium contains MCP-1 and stimulates migration of blood monocytes. Ingramon inhibited the effect of glioma-conditioned medium on monocyte migration.
Sobre autores
T. Krasnikova
Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
Autor responsável pela correspondência
Email: tlkrasnikova@gmail.com
Rússia, Moscow
T. Arefieva
Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
Email: tlkrasnikova@gmail.com
Rússia, Moscow
E. Pylaeva
Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
Email: tlkrasnikova@gmail.com
Rússia, Moscow
M. Sidorova
Russian Cardiology Research-and-Development Centre, |Ministry of Health of the Russian Federation
Email: tlkrasnikova@gmail.com
Rússia, Moscow